Double immune attack: new combo therapy targets hard-to-treat nose and throat cancer

NCT ID NCT07101744

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 09, 2026 · Updated 8 times

Summary

This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus a targeted antibody (nimotuzumab) in 41 adults with recurrent or metastatic nasopharyngeal carcinoma that worsened after standard first-line chemotherapy. The goal is to see if this triple therapy can shrink tumors and improve survival with manageable side effects. Participants must be 18-70 years old and in good general health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangdong, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

FIRST-LINE TREATMENT FAILURE NASOPHARYNGEAL CARCINOMA NASOPHARYNGEAL CARCINOMA (NPC)